This Federal Supply Schedule (FSS) contract, awarded to Novo Nordisk Inc., provides the U.S. federal government with a wide range of pharmaceutical and drug products, including those related to diabetes care, rare bleeding disorders, growth hormone disorders, and obesity. The $553,107,000 multiple-award IDV, which has an ultimate completion date of March 1, 2026, falls under the Pharmaceuticals and Drugs (FSS-61-IB) master schedule.
The contract aims to leverage Novo Nordisk's manufacturing capabilities to ensure an uninterrupted, cost-effective supply of critical medications for federal health programs, such as the VA, Department of Defense, Bureau of Prisons, and Indian Health Service. Task orders placed under this IDV facilitate the distribution of these specialized drugs to various federal customers through 2025. As a global healthcare company, Novo Nordisk is well-positioned to meet the government's need for high-quality pharmaceutical products that address the unique health challenges facing veteran and military populations, as well as other federal beneficiaries.
Generated 2/20/25, 9:06 AM